Breakthrough Nasal Spray Vaccine Protects Mice Against All Respiratory Threats

Revolutionary Approach to Universal Protection

Stanford Medicine researchers have achieved what scientists once thought impossible: developing a single vaccine that protects against viruses, bacteria, and allergens simultaneously. In the study that was published Nov. 19 in Science, researchers showed that vaccinated mice were protected against SARS-CoV-2 and other coronaviruses, Staphylococcus aureus and Acinetobacter baumannii (common hospital-acquired infections), and house dust mites (a common allergen) . The experimental nasal spray, known as GLA-3M-052-LS+OVA, represents a radical departure from traditional vaccine design.

Unlike conventional vaccines that target specific pathogens, this breakthrough treatment works by mimicking the communication signals between immune cells. The new vaccine doesn't try to mimic any part of a pathogen; instead, it mimics the signals that immune cells use to communicate with each other during an infection. This novel strategy integrates the two branches of immunity — innate and adaptive — creating a feedback loop that sustains a broad immune response .

Remarkable Breadth of Protection

When given to mice, the vaccine protected them for at least three months against multiple disease-causing viruses and bacteria — including the SARS-CoV-2 virus that causes COVID-19 — and even quelling responses to respiratory allergens . The protection extends far beyond what researchers initially expected, covering everything from common cold viruses to hospital-acquired bacterial infections.

The vaccine's effectiveness against allergens proves particularly intriguing. They exposed the mice to a protein from house dust mites, a common trigger for allergic asthma. Allergic reactions are caused by a type of immune response known as Th2 response. Unvaccinated mice showed a strong Th2 response and mucus accumulation in their airways. The vaccine quelled the Th2 response and vaccinated mice maintained clear airways .

The prolonged innate response lowers the amount of virus in the lungs by 700-fold. And viruses that slip through this initial defense are met with a swift adaptive response in the lungs. "The lung immune system is so ready and so alert that it can launch the typical adaptive responses — virus-specific T cells and antibodies — in as little as three days, which is an extraordinarily short length of time," Pulendran said .

Path to Human Application

Lead researcher Bali Pulendran envisions a future where seasonal respiratory protection becomes dramatically simplified. "Imagine getting a nasal spray in the fall months that protects you from all respiratory viruses including COVID-19, influenza, respiratory syncytial virus and the common cold, as well as bacterial pneumonia and early spring allergens," Pulendran said . Such a development could revolutionize how we approach respiratory disease prevention.

The researchers hope to test the vaccine in humans next, first in a Phase I safety trial, then, if successful, in a larger trial in which vaccinated people are exposed to infections. Pulendran thinks two doses of a nasal spray would be enough to provide protection in humans . The timeline for human availability remains optimistic but realistic.

Future Implications and Timeline

In the best case scenario, with enough funding, Pulendran estimates a universal respiratory vaccine might be available in five to seven years. It could be a bulwark against new pandemics and simplify seasonal vaccinations . The potential applications extend beyond routine healthcare into pandemic preparedness, offering a first line of defense against emerging respiratory threats.

The research builds on previous work with the tuberculosis vaccine BCG, which demonstrated that activating both innate and adaptive immunity could provide broad protection. This new synthetic approach takes that concept further, creating a targeted solution that could transform respiratory medicine. "This could serve as an early pandemic countermeasure, providing broad protection before strain-matched vaccines are available," they wrote. "Outside pandemic settings, seasonal administration could protect against influenza, common cold viruses, RSV, and other respiratory threats—ultimately paving the way toward a truly universal vaccine" .